At Greenwich Biosciences, all colleagues share a passion for the work we do. We bring years of experience in researching, developing and commercializing novel, breakthrough therapies and are driven by the determination to bring these life-changing medicines to those who need them most.

Our People

Executive Bios

Justin Gover

Justin Gover

Chief Executive Officer

Justin Gover has served as Chief Executive Officer of GW Pharmaceuticals plc since January 1999, shortly after the company was founded. He has 21 years of experience in the pharmaceutical industry.

As Chief Executive Officer, Mr. Gover has been the lead executive responsible for the running of the company’s operations, leading equity financings and business development activities. He raised initial rounds of private capital, following which led the company’s initial public offering on the AIM stock exchange in London in 2001, and more recently led GW’s initial public offering on Nasdaq in 2013. In total, he has led equity financing rounds which have raised approximately $900 million.

In 2015, Mr. Gover relocated to the US to open the company’s US headquarters in California.

Prior to joining GW, Mr. Gover was Head of Corporate Affairs at Ethical Holdings plc, a UK-based Nasdaq listed company, where he was responsible for the company’s strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings, and investor relations.

Mr. Gover holds an MBA. from the INSEAD business school in France and a BSc (Hons) from Bristol University.

Volker Knappertz

Dr. Volker Knappertz

Chief Medical Officer

Dr. Volker Knappertz has served as our Chief Medical Officer since May 2017. Dr. Knappertz has over 25 years of clinical trial experience and 17 years of pharmaceutical drug development experience, holding leadership positions with responsibilities for managing international clinical trial and medical affairs programs.

Most recently, as the Vice President of clinical development for multiple sclerosis, oncology, and biosimilar products at Teva Pharmaceuticals, Dr. Knappertz oversaw multiple regulatory submissions and approvals in the US, Canada, Europe, and Japan. Prior to joining Teva in 2012, Dr. Knappertz served in clinical and medical roles Central Nervous System, Cardiovascular, and biologics at Bayer Pharmaceuticals and AstraZeneca. 

Dr. Knappertz is a US Board certified neurologist who received his residency training at Yale University, New Haven, CT, where he served as chief resident and was fellowship trained at Wake Forest University, Winston-Salem, NC. He received his clinical scientist training and MD as well as a doctorate degree in research on glioblastoma from the University at Cologne in Germany. 

Julian Gangolli

Julian Gangolli

President, North America

Julian Gangolli has served as President, North America, since his appointment in June 2015. Mr. Gangolli has more than 2 decades of senior management experience with large pharmaceutical, specialty pharmaceutical, and start‐up biotechnology companies.

Prior to joining GW, Mr. Gangolli was, from 2004 until April 2015, President of the North American Pharmaceutical division of Allergan Inc, with responsibility for a 1,400-person integrated commercial operation with sales exceeding $3.8 billion in 2014. As a Corporate Vice President and member of the Executive Committee, Allergan’s most senior leadership team overseeing worldwide operations, Mr. Gangolli was an integral part of the executive management team that transformed Allergan into one of the leading specialty pharmaceutical companies in the US.

Prior to Allergan, Mr. Gangolli was Vice President, Sales and Marketing at VIVUS, Inc., where he established from inception a fully functioning commercial operation. Prior to VIVUS, Mr. Gangolli held roles at Syntex Pharmaceuticals, Inc. and Ortho-Cilag Pharmaceuticals Ltd. in the UK.

Mr. Gangolli was raised in the UK, received a BSc (Honors) in Applied Chemistry from Kingston University in England, and is a US citizen.

Scott Giacobello

Scott Giacobello

Chief Financial Officer

Scott Giacobello brings 25 years of finance and operational experience to GW Pharmaceuticals plc. He is an accomplished executive who most recently, and until its acquisition by Allergan, Inc. in late 2016, served as Chief Financial Officer for Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders.

From 2008 through 2015, Mr. Giacobello held senior level finance positions at Allergan, Inc., most recently serving as Vice President of Finance for Global Research & Development. While at Allergan, he also served as Vice President of Corporate Finance and Vice President of Internal Audit & Compliance. 

Scott’s previous experience includes financial positions at the Black & Decker Corporation and Ernst & Young, LLP. Mr. Giacobello holds a bachelor’s degree in business administration from the University of Notre Dame and is a Certified Public Accountant.  

Douglas Snyder

Douglas Snyder

Chief Legal Officer

Douglas Snyder has served as GW Pharmaceuticals plc's Chief Legal Officer since July 2017. He brings more than 20 years of experience providing counsel in the pharmaceutical industry, at the Food and Drug Administration (FDA), and in private practice.

Prior to joining GW, Doug led the legal and compliance teams as Senior Vice President, General Counsel, and Secretary for Actelion US. Prior to that, Doug held the position of Senior Vice President, General Counsel, Secretary at Eisai Inc., where he led the Legal, Compliance, Legislative Affairs, Internal Audit and Security Group.  

From 1999-2005, Doug was Vice President, Associate General Counsel for GlaxoSmithKline. During his tenure at GSK, Doug managed the legal and communications strategies related to some of the company’s most high profile matters concerning the New York Attorney General, the US Department of Justice, and the FDA. 

Before joining the pharmaceutical industry, Doug held the role of Associate General Counsel for the FDA, where he counseled the Commissioner, appeared before Congress in key initiatives, and led the initial False Claims/Kickback cases against the pharmaceutical industry.